Tumor microenvironment evaluation and tumor intrinsic genomic features predict anti-PD-1 response of metastatic gastric cancer: Results from phase II clinical trial and multi-omics data

被引：1
|
作者：
Zeng, Dongqiang [1 ]
Liao, Wangjun [1 ]
Kim, Kyoung Mee [2 ]
Shi, Min [1 ]
Zhou, Rui [1 ]
Yu, Yunfang [3 ]
Ye, Zilan [1 ]
Wu, Jiani [1 ]
机构：
[1] Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China
[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[3] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-6655
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6655
引用
收藏
页数：2
相关论文
共 45 条
  • [1] Tumor microenvironment evaluation to predict anti-PD-1 response of advanced gastric cancer: Results from a multicenter prospective clinical trial.
    Liao, Wangjun
    Shi, Min
    Zeng, Dongqiang
    Luo, Huiyan
    Xiao, Jian
    Ye, Feng
    Xiong, Hailin
    Yuan, Xia
    Huang, Yisheng
    Li, Yongqiang
    Huang, Na
    Wu, Jianhua
    Li, Shaowei
    Zheng, Siting
    Wu, Jiani
    Sun, Li
    Rong, Xiaoxiang
    Wang, Chunlin
    Guo, Jian
    Deng, Qiong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 415 - 415
  • [2] Tumor microenvironment evaluation to predict pembrolizumab benefit of metastatic gastric cancer: Results from phase II clinical trial
    Zeng, Dongqiang
    Liao, Wangjun
    Shi, Min
    Zhou, Rui
    Huang, Na
    Yu, Yunfang
    Peng, Wenying
    Wu, Jiani
    Ye, Zilan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [3] Durable anti-tumor response of nivolumab (anti-PD-1 antibody) for platinum-resistant ovarian cancer; phase II clinical trial with nivolumab
    Hamanishi, J.
    Mandai, M.
    Matsumura, N.
    Abiko, K.
    Baba, T.
    Yamaguchi, K.
    Konishi, I.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 23 - 23
  • [4] MFSD2A potentiates gastric cancer response to anti-PD-1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response
    Zhang, Bin
    Wang, Chun-Mei
    Wu, Hao-Xiang
    Wang, Feng
    Chai, Yang-Yang
    Hu, Ye
    Wang, Bing-Jing
    Yu, Zhou
    Xia, Rong-Hua
    Xu, Rui-Hua
    Cao, Xue-Tao
    CANCER COMMUNICATIONS, 2023, 43 (10) : 1097 - 1116
  • [5] Interim response evaluation from a phase II study of capecitabine, oxaliplatin, and anti-PD-1 in dMMR esophagogastric cancer (AuspiCiOus trial)
    Bos, J.
    Brugman, C. P.
    Bennink, R.
    Verhoeven, L.
    Westdorp, H.
    Creemers, G-J.
    Mohammad, N. Haj
    Derks, S.
    van Laarhoven, H. W. M.
    ANNALS OF ONCOLOGY, 2024, 35 : S880 - S880
  • [6] Efficacy and safety of sintilimab (anti-PD-1 mAb) for advanced cervical cancer: Results from a Phase II trial
    Gao, Qinglei
    Wang, Jing
    Xu, Qin
    Tang, Ying
    Zhang, Jieqing
    Chang, Baoping
    Xia, Bairong
    Duan, Wei
    Wang, Danbo
    Zhu, Lijing
    An, Ruifang
    Zhang, Guonan
    Tang, Yaling
    Huang, Jianli
    Zhang, Xiang
    Qiu, Hui
    Ji, Wenting
    Li, Li
    Zhu, Jianqing
    Ma, Ding
    CANCER RESEARCH, 2023, 83 (08)
  • [7] Targeting LHPP in neoadjuvant chemotherapy resistance of gastric cancer: insights from single-cell and multi-omics data on tumor immune microenvironment and stemness characteristics
    You-Xin Gao
    Xiao-Jing Guo
    Bin Lin
    Xiao-Bo Huang
    Ru-Hong Tu
    Mi Lin
    Long-Long Cao
    Qi-Yue Chen
    Jia-Bin Wang
    Jian-Wei Xie
    Ping Li
    Chao-Hui Zheng
    Ying-Hong Yang
    Chang-Ming Huang
    Jian-Xian Lin
    Cell Death & Disease, 16 (1)
  • [8] RECIST 1.1, Choi and mChoi criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with Regorafenib and anti-PD-1 antibody
    Li, Lu
    Xu, Ying
    Yang, Yi
    Ye, Feng
    Zhang, Hongmei
    Zhou, Aiping
    Zhao, Xinming
    EUROPEAN JOURNAL OF RADIOLOGY, 2021, 141
  • [9] GLS-010, a novel fully human anti-PD-1 mAb in patients with advanced tumor: Preliminary results of a Phase Ib clinical trial
    Shen, Lin
    Gong, Jifang
    Song, Yuqin
    Ye, Dingwei
    Lu, Zhihao
    Wang, Siyang
    Peng, Peijian
    Chen, Jianhua
    Jiang, Ou
    Zhang, Guojun
    Bai, Yuxian
    Pan, Jianji
    Ma, Chunguang
    Chen, Li
    Ba, Yi
    Li, Qi
    Lu, Ping
    Zhang, Lingli
    Yin, Xianli
    Gu, Shanzhi
    Zhang, Huilai
    Su, Hang
    Jiang, Yongsheng
    Cao, Bangwei
    Han, Weiqing
    Sun, Yan
    Zhang, Feng
    Ouyang, Weiwei
    Dong, Haiying
    Guo, Jianming
    Guo, Yabing
    Xu, Chongyuan
    Qi, Junyuan
    Wang, Li
    Lv, Jun
    Wang, Xiang
    Chen, Chris
    Li, Jing
    Zheng, Yong
    Jin, Ge
    Yang, Yining
    Zhao, Guodong
    Yang, Fan
    Xu, Kehui
    Liang, Xiangying
    Pan, Zhaoyang
    Meng, Haijin
    CANCER RESEARCH, 2020, 80 (16)
  • [10] Macrophage determines immnophenotype and predicts anti-PD-L1 response of urothelial cancer: Results from phase II clinical trial.
    Zeng, Dongqiang
    Ye, Zilan
    Wang, Gaofeng
    Fan, Xinxiang
    Wu, Jiani
    Huang, Yiqiang
    Li, Nailin
    Shi, Min
    Liao, Wangjun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345